WaveMan
WaveMan · Company
ISPC · Ispecimen Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ISPC iSpecimen (ISPC) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Services-commercial physical & biological research · CIK 0001558569
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
2
13F, latest reported quarter

iSpecimen insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for iSpecimen Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Bielak Benjamin
Chief Info Officer & Secretary
BUY
2023-09-15 SECtraded 2023-09-14
18,000
$13.0K
-99.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 21.3% of the 84,348 shares held after it.
  • No other insider bought within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Info Officer & Secretary Bielak Benjamin bought about $13.0K of ISPC on Sep 14, 2023, the largest insider purchase at the company since 2021; 2 funds added in the latest 13F quarter.
Curley Tracy
CEO, CFO and Treasurer
BUY
2023-06-01 SECtraded 2023-05-31
4,400
$5.5K
-99.9%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Nov 17, 2021.
  • +1.3% median (+1.3% mean) 90-day return after 2 previous buys.
  • The trade is 8.9% of the 49,541 shares held after it.
  • No other insider bought within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO, CFO and Treasurer Curley Tracy bought about $5.5K of ISPC on May 31, 2023, the largest insider purchase at the company since 2021; 2 funds added in the latest 13F quarter.
Curley Tracy
Chief Financial Officer
BUY
2021-11-17 SEC
2,000
$10.2K
-100.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 16, 2021.
  • The trade is 20.0% of the 10,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Curley Tracy bought about $10.2K of ISPC on Nov 17, 2021; 1 other insider bought within 30 days and 2 funds added in the latest 13F quarter.
UNKNOWN
Director
BUY
2021-11-29 SECtraded 2021-11-16
1,000
$5.2K
-100.0%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Nov 15, 2021.
  • -12.8% median (-12.1% mean) 90-day return after 5 previous buys.
  • The trade is 0.1% of the 1,314,524 shares held after it.
  • 1 other insider bought within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director UNKNOWN bought about $5.2K of ISPC on Nov 16, 2021; 1 other insider bought within 30 days and 2 funds added in the latest 13F quarter.
Curley Tracy
Chief Financial Officer
BUY
2021-11-17 SECtraded 2021-11-16
8,000
$41.8K
-100.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 8,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 2 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Curley Tracy bought about $41.8K of ISPC on Nov 16, 2021, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 2 funds added in the latest 13F quarter.
11 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 6 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
2 funds bought in last quarter
the lowest in Pharma & Biotech
Revenue
-79.2% year over year
below 87% of Pharma & Biotech
Margin
-543.7% net margin
below 78% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
6.4% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
more than 58% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ISPC

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-97.3%12M
-97%-61%-24%+12%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ISPC: institutional holders (13F)

13F holdings, latest reported quarter
UBS Group AG
32,037 sh
$84.9K
JANE STREET GROUP, LLC
24,414 sh
$64.7K
IFP Advisors, Inc
8,200 sh
$1.5K
Tower Research Capital LLC (TRC)
219 sh
$580
BlackRock, Inc.
71 sh
$188

Congress trades in ISPC

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ISPC planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ISPC mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$20.7K position · as of 2026-05-31
0.0%
Fidelity Nasdaq Composite Index Fund
$139 position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$82 position · as of 2026-06-30
0.0%
Fidelity Total Market Index Fund
$92 position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 2 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ISPC financials

Revenue growth
-79.2%
XBRL, annual
Net margin
-543.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$466.3K
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
1.98x
LongTermDebt as filed 2022-09-30 (45 months older than the period end) (includes the current portion); equity 2026-06-30
Cash flow to debt
-2.04x
TTM operating cash flow over LongTermDebt as filed 2022-09-30 (45 months older than the period end) (includes the current portion)
Return on equity
-968.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-170.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-677.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$1.1M
market value at close 2026-10-26 on 2026-08-14 shares, plus LongTermDebt as filed 2022-09-30 (45 months older than the period end) (includes the current portion), minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$1.9M$9.3M$9.9M$10.4M
Operating income-$9.0M-$12.7M-$11.2M-$10.2M
Net income-$10.5M-$12.5M-$11.1M-$10.2M
EPS (diluted)-2.28-17.58-24.55-1.16
Operating cash flow-$4.2M-$8.3M-$5.8M-$5.8M
Cash$6.9M$1.9M$2.3M$15.3M
SEC XBRL, fiscal years, as known on 2026-10-28

ISPC Stock Sonar score 5/7 axes

Find similar shapesCompare

ISPC ranks highest on risk and compliance (75th percentile) and financial health (27th), and lowest on institutional and government (1st), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
6
Inputs
  • Return on equity-968.5% · 4 pct, sector of 545
  • Return on assets-170.1% · 13 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-677.9% · 2 pct, sector of 576
Financial health
27
Inputs
  • Debt to equity1.98x · 10 pct, sector of 352
  • Cash flow to debt-2.04x · 44 pct, sector of 371
Growth
13
Inputs
  • Revenue growth, YoY-79.2% · 13 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
0
Inputs
  • Funds adding, latest quarter2 · 0 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
75
Inputs
  • Short interest, % of float+6.4% · 52 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+1.4% · 97 pct, sector of 511
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies